CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 200 target
Drug / intervention
Small RNA sequencing +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07226154
NCT07226154N/ARecruitingOn TrackUpdated 7mo ago
CompareCT.gov

An Exosomal miRNA Based Predictive Model for Personalized Neoadjuvant Chemotherapy Selection in Pancreatic Ductal Adenocarcinoma

City of Hope Medical Center·observational·Posted Nov 10, 2025·Updated Nov 21, 2025

In Brief

An observational study evaluating Small RNA sequencing and PRECEPT assay (qRT-PCR validation) for Pancreatic Ductal Adenocarcinoma. Currently recruiting, targeting 200 participants across 1 site.

Detailed Summary

This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Ductal Adenocarcinoma
CountriesUnited States
Collaborators--

Timeline

N/ARecruitingOverdue
20252026
First PostedNov 10, 2025
Enrollment StartNov 15, 2024
Primary CompletionJun 18, 2026
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 8 months ago

Interventions

Small RNA sequencingother

High-throughput small RNA sequencing performed on pre-treatment plasma samples from PDAC patients in the Discovery cohort to identify candidate microRNAs associated with neoadjuvant chemotherapy response. Sequencing data were analyzed to detect differentially expressed miRNAs between responder (CR + PR + SD) and non-responder (PD) groups.

PRECEPT assay (qRT-PCR validation)other

Quantitative reverse transcription PCR (qRT-PCR)-based validation assay performed on pre-treatment plasma samples in the Training and Validation cohorts. Candidate microRNAs identified in the Discovery cohort by small RNA sequencing were tested using the PRECEPT assay to develop and validate a predictive miRNA panel for neoadjuvant chemotherapy response.